Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER)

Cardiovascular Drugs and Therapy

Volumn 29, Issue 2, 2015, Pages 179-185

  Asakura, Masanori ^a   Yamamoto, Haruko ^a   Asai, Kuniya ^b   Hanatani, Akihisa ^c   Hirata, Ken ichi ^d   Hirayakma, Atsushi ^e   Kimura, Kazuo ^f   Kobayashi, Youichi ^g   Momomura, Shin ichi ^h   Nakagawa, Yoshihisa ⁱ   Nishi, Yutaro ^j   Saito, Yoshihiko ^k   Satoh, Yasuhiro ^l   Yamada, Takahisa ^m   Yamashina, Akira ⁿ   Yasuda, Satoshi ^a   Yoshikawa, Tsutomu ^o   Kada, Akiko ^a,p   Uesaka, Hiroyuki ^a   Kitakaze, Masafumi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^g SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h JICHI MEDICAL UNIVERSITY   (Japan)

ⁱ TENRI HOSPITAL   (Japan)

^j ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^k NARA MEDICAL UNIVERSITY   (Japan)

^l Department of Pediatrics   (Japan)

^m OSAKA GENERAL MEDICAL CENTER   (Japan)

ⁿ TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^o SAKAKIBARA HEART INSTITUTE   (Japan)

^p NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

Acute heart failure; Acute myocardial infarction; Aldosterone; Cardiac death; Eplerenone; Re hospitalization

Indexed keywords

EPLERENONE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ACUTE DISEASE; ADULT; ANALOGS AND DERIVATIVES; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EARLY INTERVENTION; FEMALE; HEART FAILURE; HUMAN; MALE; MULTICENTER STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ACUTE DISEASE; ADULT; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; EARLY MEDICAL INTERVENTION; FEMALE; HEART FAILURE; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE; YOUNG ADULT;

EID: 84939978840     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6565-2     Document Type: Article

References (25)

1. Chang PP, Chambless LE, Shahar E, et al. Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the atherosclerosis risk in communities study). Am J Cardiol. 2014;113:504–10.
2. Guidelines for treatment of acute heart failure (JCS 2011). Cir J: Off J Jpn Circ Soc. 2013;77:2157–201.
3. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.
4. Mentz RJ, Bakris GL, Waeber B, et al. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013;167:1677–87.
5. O’Connor CM, Fiuzat M, Swedberg K, et al. Influence of global region on outcomes in heart failure beta-blocker trials. J Am Coll Cardiol. 2011;58:915–22.
6. Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev. 2004;9:179–85.
7. Sato N, Kajimoto K, Keida T, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND registry). Circ J: Off J Jpn Circ Soc. 2013;77:944–51.
8. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–17.
9. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.
10. Girerd N, Pang PS, Swedberg K, et al. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail. 2013;15:1228–35.
11. Gheorghiade M, Pang PS, Ambrosy AP, et al. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. 2012;17:485–509.
12. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
13. McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail. 2011;13:929–36.
14. Cleland JG, Coletta AP, Buga L, et al. Clinical trials update from the American heart association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. Eur J Heart Fail. 2011;13:460–5.
15. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hyperten Suppl: Off J Int Soc Hypertens. 2005;23:S9–17.
16. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2010;55:2062–76.
17. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circ. 2007;116:1482–7.
18. O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138:78–86.
19. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798–803.
20. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. Jama. 2013;310:2533–43.
21. Hernandez AF, O’Connor CM, Starling RC, et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J. 2009;157:271–7.
22. Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting beta1-selective blocker landiolol with digoxin (J-Land Study). Circ J: Off J Jpn Circ Soc. 2013;77:908–16.
23. Montalescot G, Pitt B, de Sa Lopez E, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study. Eur Heart J. 2014;35:2295–302.
24. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92.
25. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483–93.